|
Match
|
Document |
Document Title |
|
|
5976532 |
Method of antithrombotic therapy using anti-GPIIb/IIIa antibodies or fragments thereof, including c7E3
Platelet-specific, chimeric immunoglobulin and immunoglobulin fragments are described. The chimeric molecules are made up of a nonhuman antigen binding region and a human constant region. Preferred...
|
|
|
5976527 |
High surface area support having bound latex particles containing oxirane groups for immobilization of substances
A high surface area system is provided with latex particles for immobilization of substances containing nucleophilic groups. The high surface area system is formed by aggregating the latex...
|
|
|
5976542 |
Compositions and methods for treatment of streptococcus pneumoniae infection
The invention relates to an isolated nucleic acid encoding Streptococcus pneumoniae IgA protease and an isolated polypeptide comprising Streptococcus pneumoniae IgA protease and methods of use...
|
|
|
5958406 |
Acne treatment with multifunctional enzyme
The invention relates to a multifunctional enzyme that can be derived from crustaceans or fish. The enzyme has at least one of a chymotrypsin, trypsin, elastase, collagenase and exo peptidase...
|
|
|
5945102 |
Crustacean and fish derived multifunctional enzyme
The invention relates to a multifunctional enzyme that can be derived from crustaceans or fish. The enzyme has at least one of a chymotrypsin, trypsin, elastase, collagenase and exo peptidase...
|
|
|
5935572 |
Composition containing protease separate from glycosidase for removing nits in treating lice infestation
A composition containing a protease and glycosidase is provided for removing nits in the treatment of lice infestation. The protease and glycosidase are separated from each other to prevent the...
|
|
|
5935573 |
Method of use of an analog of Haemophilus influenzae Hin47 with reduced protease activity
An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially...
|
|
|
5928640 |
Use of enzymes, especially bromelain, in the treatment of diarrhoea
Enzymes, especially proteolytic enzymes such as bromelain, have been found to inhibit the action of heat-labile toxin (LT) of enterotoxigenic Escherichia coli. They are therefore useful in the...
|
|
|
5925739 |
Pharmaceutical formulation for subcutaneous intramuscular or intradermal administration of factor VIII
The present invention relates to a pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration comprising coagulation factor VIII or factor IX and use thereof for...
|
|
|
5922322 |
Fibrin(ogen) degradation and clot lysis by fibrinolytic matrix metalloproteinase
The invention provides a method of causing degradation of fibrin(ogen) (i.e., fibrin, fibrinogen, and related substances) by means of a fibrinolytic metalloproteinase, preferably an endogenous...
|
|
|
5916557 |
Methods of repairing connective tissues
The present invention relates to the use of an ECM-altering enzymatic activity, such as a proteoglycanase or a protease, to stimulate the generation of cartilage tissue by inducing chondrocytes to...
|
|
|
5902615 |
Nutritional composition resulting from maize steeping
The invention relates to a new nutritional composition resulting from maize steeping. This composition comprises an inorganic phosphorous concentration to total phosphorus concentration ratio...
|
|
|
5897860 |
Method for controlling bleeding and microbial infections by administering thrombin, casein kinase II, and sphingosine
The present invention relates to a hemostatic composition comprising at least 0.1 NIH U/ml of thrombin, about 0.01 mU/ml of casein kinase II, and from 10 ng/ml to 100 ng/ml of sphingosine or a...
|
|
|
5869314 |
Tissue plasminogen activators and derivatives thereof as produced by recombinant means
Tissue plasminogen activators (t-PAs) and derivatives thereof are produced in useful quantities using recombinant DNA techniques. Specific derivatives include amino acid deletion derivatives and...
|
|
|
5866121 |
Method for targeting degradation of intracellular proteins
A method for selective targeted degradation of intracellular proteins in situ by inducing in cells a production of an agent comprising N-terminal domain as well as a C-terminal domain. The...
|
|
|
5863534 |
Polypeptide having factor Xa inhibitory method of reducing blood coagulation with a novel polypeptide having factor Xa inhibitory activity
A novel polypeptide derived from the leech Hirudo medicinalis was found to be able to inhibit Factor Xa thereby reducing the extent of blood coagulation. The polypeptide is useful in treating...
|
|
|
5858969 |
Therapeutic methods employing sialylated glycoforms of soluble complement receptor 1 (SCR 1)
Provided are therapeutic methods employing preparations of recombinant soluble Complement Receptor type 1 (sCR1) defined with respect to the distribution of sCR1 glycoforms. The methods are...
|
|
|
5858357 |
Pharmaceutical composition containing an isolated protease proenzyme, amylase, and aprotinin
The invention is directed to a pharmaceutical preparation with a modulatory effect on malignant tumors, which contains a combination of protease proenzymes and amylases in a ratio between 1:100 and...
|
|
|
5853705 |
Anti-aging cosmetic composition
An anti-aging cosmetic composition in which is blended an enzymolyzed substance obtained by treating by one or more enzymes an alkali extract of a hypoallergenic rice obtained by treating rice in...
|
|
|
5849296 |
Crosslinked protein crystals
A protein such as an enzyme or antibody is immobilized by crosslinking crystals of the protein with a multifunctional crosslinking agent. The crosslinked protein crystals may be lyophilized for...
|
|
|
5843436 |
Method of preventing and treating bacterial infection of sutures and prosthetic devices, and promoting ingress of leukocytes into tumor foci
An agent capable of inhibiting signalling mediated by a β 1 integrin cell surface receptor of leukocyte cells will treat a bacterial infection associated with a surface of a foreign body over and...
|
|
|
5830849 |
Vampire bat salivary plasminogen activators
Purified plasminogen activator proteins obtained or derived from the vampire bat Desmodus rotundus saliva and salivary glands, methods for purifying the proteins, DNA sequences encoding these...
|
|
|
5830468 |
Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
The invention provides a method of causing the degradation of fibrin(ogen) (i.e., fibrin, fibrinogen, and related substances) by means of a fibrinolytic metalloproteinase, such as MMP-3. The method...
|
|
|
5821105 |
Tissue plasminogen activator having zymognic or fibrin specific properties
Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of...
|
|
|
5811112 |
Oil-in-water cosmetic emulsions containing a stabilized protease
Cosmetic oil-in-water emulsions which are intended to be left on the skin after application (not rinsed off) the emulsions incorporating a stabilized protease. The cosmetic emulsions useful in...
|
|
|
5801022 |
Method of producing a product with crosslinked crystals of thermolysin
A protein such as an enzyme or antibody is immobilized by crosslinking crystals of the protein with a multifunctional crosslinking agent such as glutaraldehyde, and if desired lyophilizing the...
|
|
|
5776452 |
Thrombosis agent
The invention provides compositions having thrombolytic effects, and comprise plasmin and a plasminogen activator. Such compositions can be administered locally or systemically. The invention also...
|
|
|
5759541 |
Recombinant fibrinogenases, the preparation and use thereof
Novel polypeptides having fibrinogenolytic properties and having amino acid sequences as SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6 indicated in the Sequence Listing, the preparation...
|
|
|
5747030 |
Pharmaceutical preparation containing plasminogen activators
The invention relates to pharmaceutical preparations containing plasminogen activators, sugars and tranexamic acid, in the form of a lyophilisate or an injection or infusion solution. In...
|
|
|
5736135 |
Method for making variant secreted proteins with altered properties
A screening method for the selection of mutagenized proteins that are normally secreted by cells is described. The method includes the development of a cloning vector for the expression of...
|
|
|
5728566 |
Tissue plasminogen activator derivatives
Tissue plasminogen activator (t-PA) derivatives are produced in useful quantifies using recombinant DNA techniques. Specific derivatives include amino acid deletion derivatives and amino acid...
|
|
|
5718915 |
Antiviral liposome having coupled target-binding moiety and hydrolytic enzyme
Complexes are prepared containing two or more different effector molecules joined to each other by a joining component. At least one of the effector molecules can bind to a target molecule and at...
|
|
|
5714144 |
Human tissue-type plasminogen activator variant
Novel human tissue-type plasminogen activator variant that a) retains substantially full biological activity b) has a modified carbohydrate structure and c) has an altered in vivo half-life. Means...
|
|
|
5707620 |
Lysine-specific Porphyromonas gingivalis proteinase
Provide herein is a substantially pure Lys-gingipain complex preparation, Lys-gingipain being characterized as having an apparent molecular mass of 105 kDa as estimated by sodium dodecyl sulfate...
|
|
|
5695753 |
Transglutaminases as immunosuppressants
A description is given of the possibility of using transglutaminases in a process for the preparation of an immunosuppressant. Additionally described is a pharmaceutical containing a...
|
|
|
5690931 |
Method for treating thromboembolic conditions via the use of multiple bolus administration of thrombolytically active proteins
Discussed are therapeutic approaches to the treatment of thrombolic conditions. The therapies use thrombolytically active proteins which function by, e.g., inhibiting reocclusion in the subject....
|
|
|
5688502 |
Animal growth promotant
A growth promotant comprising microgranules having a core consisting of one or more enzymes selected from: i) protein digesting enzymes; ii) carbohydrate digesting enzymes; iii) fat digesting...
|
|
|
5688503 |
Modification of plasminogen activators
Phosphorylated plasminogen activator, such as phosphorylated pro-urokinase (pro-u-PA), which is substantially free from unphosphorylated plasminogen activator, may be obtained by phosphorylating...
|
|
|
5679344 |
Glucosamine composition and method
A glucosamine-containing composition that includes an anti-inflammatory proteolytic enzyme composition to increase the rapidity of physiological availability of the glucosamine and the method of...
|
|
|
5665366 |
Skin care method and composition
A composition for topical application to the skin for alleviation or prevention of dry flaky skin conditions, dandruff or ache comprising one or more stratum corneum trypsin-like enzymes. The...
|
|
|
5665353 |
Composition containing an analog of haemophilus Hin47 with reduced protease activity
An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially...
|
|
|
5662901 |
Enzymatic grain conditioner and methods of using it
The invention comprises two grain conditioners. The first grain conditioner, which is suitable for use on all grains, comprises a pectinase, a protease, a beta-glucanase and an amylase. The second...
|
|
|
5639857 |
Ultrapurification of factor IX and other vitamin k-dependent proteins
A method of recovering active, highly purified and concentrated vitamin K-dependent proteins from plasma, concentrate or mixtures of proteins produced by recombinant DNA technology using an...
|
|
|
5637299 |
Enhancement of thrombolytic therapy with deglycosylated forms of plasminogen
This invention provides an improved method for enhancing the activity of thrombolytic agents, including t-PA, scu-PA, tcu-PA, streptokinase, acylated plasminogen-streptokinase activator complex...
|
|
|
5632986 |
Phospholipid-targeted thrombolytic agents
Conjugates with an affinity for phospholipids are disclosed. The conjugates comprise a first compound having affinity for phospholipids, with a binding constant that is not greater than about 10 -7...
|
|
|
5626841 |
Use of intra-platelet urokinase-type plasminogen activators for long-term inhibition of thrombosis
A method of adjunctive therapy to inhibit reocclusions in a patient, e.g., after thrombolytic therapy or angioplasty, by administering to the patient a bolus of an amount of purified pro-urokinase...
|
|
|
5620688 |
Methods of inhibiting the activation of Factor XIII
Compositions and methods for inhibiting the activation and/or active state of a precursor protein are provided. Compositions provided can bind to a cleavage site of a precursor protein. Also...
|
|
|
5618710 |
Crosslinked enzyme crystals
A protein such as an enzyme of antibody is immobilized by crosslinking crystals of the protein with a multifunctional crosslinking agent. The crosslinked protein crystals may be lyophilized for...
|
|
|
5612029 |
Tissue plasminogen activator glycosylation variants with improved therapeutic properties
The invention concerns tissue plasminogen activator (t-PA) variants which are glycosylated at any of positions 103-105, and are devoid of functional carbohydrate structure at position 117 of...
|
|
|
5607671 |
Medical use, a medical method and a pharmaceutical preparation
The invention concerns medical use, a medical method and a pharmaceutical preparation. The invention allows the action of β-lactam antibiotics to be targeted and their side effects to be reduced...
|